20 34

Cited 0 times in

Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma

Authors
 Yu Ri Kim  ;  Soo-Jeong Kim  ;  June-Won Cheong  ;  Haerim Chung  ;  Ji Eun Jang  ;  Yundeok Kim  ;  Woo-Ick Yang  ;  Yoo Hong Min  ;  Jin Seok Kim 
Citation
 Oncotarget, Vol.8(54) : 92312-92323, 2017 
Journal Title
 Oncotarget 
Issue Date
2017
Keywords
Epstein-Barr virus ; peripheral T-cell lymphoma ; prognostic score ; whole blood
Abstract
Because there are few studies regarding the clinical impact of circulating EBV-DNA in peripheral T-cell lymphomas (PTCLs), we tried to evaluate the role of EBV-DNA in whole blood as a prognostic factor for PTCL. We retrospectively reviewed 110 PTCL patients with median age of 63 (20-94) years. Forty-seven patients (42.7%) showed positive results for EBV-DNA, and these patients also had stage III/IV disease, elevated lactic dehydrogenase, and low albumin level (P = 0.007, P = 0.004, P = 0.002, respectively). The 5-year overall survival (OS) and progression free survival (PFS) were 21.0% and 18.0%. Univariable analysis showed that positive EBV-DNA was related with inferior OS and PFS (P = 0.015 and P < 0.001, respectively). Multivariable analysis showed that poor performance status, extranodal involvement more than one site and positive EBV-DNA results were related with OS and PFS (P < 0.001, P < 0.001, P = 0.007 and P = 0.001, P = 0.002, P < 0.001, respectively). Using these three variables, we made a new prognostic model which classified patients on risk as follows: low, no adverse factors; intermediate, 1 factor; or high, 2-3 factors. The new prognostic model could stratify the three groups for OS and PFS better than either international prognostic index or prognostic index of PTCL-u, and showed statistical significance in PTCL, not otherwise specified. This study suggests that whole blood EBV-DNA is related with aggressive clinical characteristics and inferior survival. The new prognostic model, which incorporates EBV-DNA, could better stratify PTCL patients.
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/161454
DOI
10.18632/oncotarget.21251
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실)
Yonsei Authors
김수정(Kim, Soo Jeong) ; 김유리(Kim, Yu Ri) ; 김윤덕(Kim, Yun Deok) ; 김진석(Kim, Jin Seok) ; 민유홍(Min, Yoo Hong) ; 양우익(Yang, Woo Ick) ; 장지은(Jang, Ji Eun) ; 정준원(Cheong, June-Won) ; 정해림(Chung, Hae Rim)
사서에게 알리기
  feedback
Files in This Item:
T201704827.pdf Download
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse